The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Treatment of Endometriosis-Associated Pain with Elagolix, an Oral GnRH Antagonist
Open accessAbstract
BACKGROUND: Endometriosis is a chronic, estrogen-dependent condition that causes dysmenorrhea and pelvic pain. Elagolix, an oral, nonpeptide, gonadotropin-releasing hormone (GnRH) antagonist, produced partial to nearly full estrogen suppression in previous studies. METHODS: We performed two similar, double-blind, randomized, 6-month phase 3 trials (Elaris Endometriosis I and II [EM-I and EM-II]) to evaluate the effects of two doses of elagolix - 150 mg once daily (lower-dose group) and 200 mg twice daily (higher-dose group) - as compared with placebo in women with surgically diagnosed endometriosis and moderate or severe endometriosis-associated pain. The two primary efficacy end points were the proportion of women who had a clinical response with respect to dysmenorrhea and the proportion who had a clinical response with respect to nonmenstrual pelvic pain at 3 months. Each of these end points was measured as a clinically meaningful reduction in the pain score and a decreased or stable use of rescue analgesic agents, as recorded in a daily electronic diary. RESULTS: A total of 872 women underwent randomization in Elaris EM-I and 817 in Elaris EM-II; of these women, 653 (74.9%) and 632 (77.4%), respectively, completed the intervention. At 3 months, a significantly greater proportion of women who received each elagolix dose met the clinical response criteria for the two primary end points than did those who received placebo. In Elaris EM-I, the percentage of women who had a clinical response with respect to dysmenorrhea was 46.4% in the lower-dose elagolix group and 75.8% in the higher-dose elagolix group, as compared with 19.6% in the placebo group; in Elaris EM-II, the corresponding percentages were 43.4% and 72.4%, as compared with 22.7% (P<0.001 for all comparisons). In Elaris EM-I, the percentage of women who had a clinical response with respect to nonmenstrual pelvic pain was 50.4% in the lower-dose elagolix group and 54.5% in the higher-dose elagolix group, as compared with 36.5% in the placebo group (P<0.001 for all comparisons); in Elaris EM-II, the corresponding percentages were 49.8% and 57.8%, as compared with 36.5% (P=0.003 and P<0.001, respectively). The responses with respect to dysmenorrhea and nonmenstrual pelvic pain were sustained at 6 months. Women who received elagolix had higher rates of hot flushes (mostly mild or moderate), higher levels of serum lipids, and greater decreases from baseline in bone mineral density than did those who received placebo; there were no adverse endometrial findings. CONCLUSIONS: Both higher and lower doses of elagolix were effective in improving dysmenorrhea and nonmenstrual pelvic pain during a 6-month period in women with endometriosis-associated pain. The two doses of elagolix were associated with hypoestrogenic adverse effects. (Funded by AbbVie; Elaris EM-I and EM-II ClinicalTrials.gov numbers, NCT01620528 and NCT01931670 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“In both trials, during the 6 months treatment, elagolix dramatically reduced dysmenorrhea and non-menstrual pelvic discomfort.”
From Hormonal treatments for endometriosis: The endocrine background (2022) · cites this paper as [173]
In the citing paper
“The results of a study in which about 1700 women with moderate or severe pain in endometriosis participated played a part in the above decision. Doses of this drug—150 mg once a day or 200 mg twice a day—significantly reduced the most common types of endometrial pain: pelvic pain and sex-related pain.”
From Endometriosis: Epidemiology, Classification, Pathogenesis, Treatment and Genetics (Review of Literature) (2021) · cites this paper as [117]
In the citing paper
“The latest drug to be approved by the Food and Drug Administration (FDA) is elagolix, a drug for the treatment of moderate to severe pain associated with endometriosis [117].”
From Endometriosis: Epidemiology, Classification, Pathogenesis, Treatment and Genetics (Review of Literature) (2021) · cites this paper as [117]
In the citing paper
“Recently, an oral GnRH antagonist (elagolix) was reported to be effective for reducing endometriosis‐related symptoms.”
From Extra-pelvic endometriosis: a review. (2020) · cites this paper as [97]
In the citing paper
“In Elaris EM-II, corresponding percentages were 49.8% and 57.8% (compared with 36.5% in the placebo group).”
From Endometriosis and Medical Therapy: From Progestogens to Progesterone Resistance to GnRH Antagonists: A Review (2021) · cites this paper as [102]
In the citing paper
“In the EM-I and -II trials, Taylor et al. [102] reported that mean decreases in BMD in the lumbar spine, femoral neck and total hip after six months of treatment were significantly greater in patients receiving elagolix than in those given a placebo (excluding femoral neck BMD at a dose of 150 mg in Elaris EM-I (Figure 3).”
From Endometriosis and Medical Therapy: From Progestogens to Progesterone Resistance to GnRH Antagonists: A Review (2021) · cites this paper as [102]
In the citing paper
“In Elaris EM-II, corresponding percentages were 43.4% and 72.4% (compared with 22.7% in the placebo group).”
From Endometriosis and Medical Therapy: From Progestogens to Progesterone Resistance to GnRH Antagonists: A Review (2021) · cites this paper as [102]
In the citing paper
“At 200 mg (twice daily), percentages were respectively 42.3%, 47.6%, 72% and 77% [102,103].”
From Endometriosis and Medical Therapy: From Progestogens to Progesterone Resistance to GnRH Antagonists: A Review (2021) · cites this paper as [102]
In the citing paper
“Overall, alleviation of both dysmenorrhea and non-menstrual pelvic pain were sustained for six months (Table 1).”
From Endometriosis and Medical Therapy: From Progestogens to Progesterone Resistance to GnRH Antagonists: A Review (2021) · cites this paper as [102]
In the citing paper
“In both studies, only women treated with elagolix at a dose of 200 mg twice daily showed a statistically significant greater reduction in dyspareunia after three months of treatment (compared with the placebo).”
From Endometriosis and Medical Therapy: From Progestogens to Progesterone Resistance to GnRH Antagonists: A Review (2021) · cites this paper as [102]
In the citing paper
“In conclusion, use of elagolix 200 mg twice daily causes strong suppression of E2 and marked improvements in dysmenorrhea, non-menstrual pelvic pain and dyspareunia, albeit at the cost of more hot flushes and a more pronounced decrease in BMD (Figure 4).”
From Endometriosis and Medical Therapy: From Progestogens to Progesterone Resistance to GnRH Antagonists: A Review (2021) · cites this paper as [102]
In the citing paper
“The percentage of patients with a decrease of >5% from baseline in lumbar spine BMD was higher in the elagolix 200 mg twice daily group in all studies.”
From Endometriosis and Medical Therapy: From Progestogens to Progesterone Resistance to GnRH Antagonists: A Review (2021) · cites this paper as [102]
In the citing paper
“Overall, the pharmacokinetic properties of elagolix at 150 mg once daily and 200 mg twice daily do not appear to be affected, to a clinically meaningful extent, by body weight, body mass index, race/ethnicity or the presence of endometriosis [102,103,107].”
From Endometriosis and Medical Therapy: From Progestogens to Progesterone Resistance to GnRH Antagonists: A Review (2021) · cites this paper as [102]
In the citing paper
“Elagolix causes a dose-dependent decrease in BMD.”
From Endometriosis and Medical Therapy: From Progestogens to Progesterone Resistance to GnRH Antagonists: A Review (2021) · cites this paper as [102]
In the citing paper
“Regarding side effects, the most frequently reported were hot flushes, depending on the dose.”
From Endometriosis and Medical Therapy: From Progestogens to Progesterone Resistance to GnRH Antagonists: A Review (2021) · cites this paper as [102]
In the citing paper
“Percentages of women experiencing hot flushes at a dose of 150 mg (once daily) were respectively 23.7%, 22.6%, 44% and 36% in Elaris-I, -II, -III and -IV.”
From Endometriosis and Medical Therapy: From Progestogens to Progesterone Resistance to GnRH Antagonists: A Review (2021) · cites this paper as [102]
In the citing paper
“In Elaris EM-I, the percentage of women who noted an improvement in non-menstrual pelvic pain was 50.4% with elagolix 150 mg once daily and 54.5% with elagolix 200 mg twice daily (compared with 36.5% in the placebo group).”
From Endometriosis and Medical Therapy: From Progestogens to Progesterone Resistance to GnRH Antagonists: A Review (2021) · cites this paper as [102]
In the citing paper
“The percentage of women who experienced a clinical improvement in dysmenorrhea was 46.4% with elagolix 150 mg once daily and 75.8% with elagolix 200 mg twice daily (compared with 19.6% in the placebo group).”
From Endometriosis and Medical Therapy: From Progestogens to Progesterone Resistance to GnRH Antagonists: A Review (2021) · cites this paper as [102]
In the citing paper
“Even if the majority of patients were satisfied with this therapy, as many as 40% of patients indicated unsatisfactory improvement of pain symptoms ( 69 ).”
From Is intracrinology of endometriosis relevant in clinical practice? A systematic review on estrogen metabolism (2022) · cites this paper as [69]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Farrar, J. T., Young, J. P., LaMoreaux, L., Werth, J. L., & Poole, M. R. (2001) · Pain · doi:10.1016/s0304-3959(01)00349-9 · Cited by 5,808
Giudice, L. C. (2010) · New England Journal of Medicine · doi:10.1056/nejmcp1000274 · Cited by 1,924
Self-citationBulun, S. E. (2009) · New England Journal of Medicine · doi:10.1056/nejmra0804690 · Cited by 1,772
Nnoaham, K. E., Hummelshoj, L., Webster, P., d’Hooghe, T., de Cicco Nardone, F., de Cicco Nardone, C., Jenkinson, C., Kennedy, S. H., & Zondervan, K. T. (2011) · Fertility and Sterility · doi:10.1016/j.fertnstert.2011.05.090 · Cited by 1,584
Simoens, S., Dunselman, G., Dirksen, C., Hummelshoj, L., Bokor, A., Brandes, I., Brodszky, V., Canis, M., Colombo, G. L., DeLeire, T., et al. (2012) · Human Reproduction · doi:10.1093/humrep/des073 · Cited by 1,070
Burney, R. O., Talbi, S., Hamilton, A. E., Vo, K. C., Nyegaard, M., Nezhat, C. R., Lessey, B. A., & Giudice, L. C. (2007) · Endocrinology · doi:10.1210/en.2006-1692 · Cited by 735
Self-citationRecurrence of endometriosis and its control
Guo, S.-W. (2009) · Human Reproduction Update · doi:10.1093/humupd/dmp007 · Cited by 719
Consensus on current management of endometriosis
Johnson, N. P., Hummelshoj, L., for the World Endometriosis Society Montpellier Consortium, Abrao, M. S., Adamson, G. D., Allaire, C., Amelung, V., Andersson, E., Becker, C., Birna Árdal, K. B., et al. (2013) · Human Reproduction · doi:10.1093/humrep/det050 · Cited by 558
Self-citationJacobson, T. A., Ito, M. K., Maki, K. C., Orringer, C. E., Bays, H. E., Jones, P. H., McKenney, J. M., Grundy, S. M., Gill, E. A., Wild, R. A., et al. (2014) · Journal of clinical lipidology · doi:10.1016/j.jacl.2014.07.007 · Cited by 469
Contribution of Bone Marrow-Derived Stem Cells to Endometrium and Endometriosis
Du, H., & Taylor, H. S. (2007) · Stem Cells · doi:10.1634/stemcells.2006-0828 · Cited by 449
Self-citation
Flagged first, then by citations
Research works printed but not linked: 4
- Brown J, 2010, Cochrane Database Syst Rev, CD008475
- Surrey ES, 2002, Obstet Gynecol, 99, 709
- Prentice A, 2000, Cochrane Database Syst Rev, CD000346
- Sagsveen M, 2003, Cochrane Database Syst Rev, CD001297
Cited by
Sorted by citations
Items 101–200 of 527
Emerging Drug Targets for Endometriosis
Dolmans, M., & Donnez, J. (2022) · Biomolecules · doi:10.3390/biom12111654 · Cited by 40
Novel pharmacological therapies for the treatment of endometriosis
Buggio, L., Dridi, D., Barbàra, G., Merli, C. E. M., Cetera, G. E., & Vercellini, P. (2022) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2022.2117155 · Cited by 38
Pokrzywinski, R. M., Soliman, A. M., Chen, J., Snabes, M. C., Coyne, K. S., Surrey, E. S., & Taylor, H. S. (2020) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2019.11.1255 · Cited by 36
Self-citationManagement of endometriosis: Toward value-based, cost-effective, affordable care
Vercellini, P., Facchin, F., Buggio, L., Barbara, G., Berlanda, N., Frattaruolo, M. P., & Somigliana, E. (2018) · Journal of Obstetrics and Gynaecology Canada · doi:10.1016/j.jogc.2017.07.011 · Cited by 36
Understanding Endometriosis: A Broad Review of Its Causes, Management, and Impact
Czubak, P., Herda, K., Niewiadomska, I., Putowski, L. T., Łańcut, M., & Masłyk, M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26188878 · Cited by 36
Wu, H., Chang, H., & Leung, P. C. K. (2020) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2020.100876 · Cited by 37
Symptom tracking in endometriosis using digital technologies: Knowns, unknowns, and future prospects
Edgley, K., Horne, A. W., Saunders, P. T. K., & Tsanas, A. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101192 · Cited by 35
Current and Emerging Treatment Options for Uterine Fibroids
Ali, M. K., Ciebiera, M., Włodarczyk, M., Alkhrait, S., Maajid, E., Yang, Q., Hsia, S., & Al-Hendy, A. A. (2023) · Drugs · doi:10.1007/s40265-023-01958-6 · Cited by 35
Male contraception: where are we going and where have we been?
Reynolds-Wright, J. J., & Anderson, R. A. (2019) · BMJ Sexual & Reproductive Health · doi:10.1136/bmjsrh-2019-200395 · Cited by 34
Pawsey, S., Mills, E. G., Ballantyne, E., Donaldson, K. M., Kerr, M., Trower, M., & Dhillo, W. S. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab108 · Cited by 34
Advances in targeting estrogen synthesis and receptors in patients with endometriosis
Clemenza, S., Vannuccini, S., Ruotolo, A., Capezzuoli, T., & Petraglia, F. (2022) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2022.2152325 · Cited by 34
Othman, E. R., Al-Hendy, A. A., Mostafa, R., Lambalk, C. B., & Mijatovic, V. (2024) · International Journal of Women s Health · doi:10.2147/ijwh.s442357 · Cited by 36
Surrey, E. S., Soliman, A. M., Agarwal, S. K., Snabes, M. C., & Diamond, M. P. (2019) · Fertility and Sterility · doi:10.1016/j.fertnstert.2019.02.031 · Cited by 32
Self-citationGonadotropin-releasing hormone analog therapeutics
Newton, C. L., Riekert, C., & Millar, R. P. (2018) · Minerva Obstetrics and Gynecology · doi:10.23736/s0026-4784.18.04316-2 · Cited by 33
Sadłocha, M., Toczek, J., Major, K., Staniczek, J., & Stojko, R. (2024) · Pharmaceuticals · doi:10.3390/ph17070827 · Cited by 34
Endometriosis Pain Management: a Review
Carlyle, D., Khader, T., Lam, D., Vadivelu, N., Shiwlochan, D., & Cho, Y. (2020) · Current Pain and Headache Reports · doi:10.1007/s11916-020-00884-6 · Cited by 34
Dyspareunia in Their Own Words: A Qualitative Description of Endometriosis-Associated Sexual Pain
Wahl, K., Imtiaz, S., Lisonek, M., Joseph, K. S., Smith, K. B., Yong, P. J., & Cox, S. (2020) · Sexual Medicine · doi:10.1016/j.esxm.2020.10.002 · Cited by 31
Research advances in drug therapy of endometriosis
Shi, J., Tan, X., Feng, G., Yuan, Z., Jiang, Z., Banda, S., Wang, L., Zheng, W., Chen, L., Yu, D., et al. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1199010 · Cited by 30
Ali, M. K., Sara, A. R., & Hendy, A. A. (2021) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2021.1900726 · Cited by 30
Tan, Z., Gong, X., Wang, C. C., Zhang, T., & Huang, J. L. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242115967 · Cited by 32
Adverse bone effects of medications used to treat non-skeletal disorders
Watts, N. B. (2017) · Osteoporosis International · doi:10.1007/s00198-017-4171-4 · Cited by 31
Self-citationDonnez, O. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10215183 · Cited by 29
Serum MicroRNA Biomarkers Regulated by Simvastatin in a Primate Model of Endometriosis
Çoşar, E., Mamillapalli, R., Moridi, I., Dulęba, A. J., & Taylor, H. S. (2018) · Reproductive Sciences · doi:10.1177/1933719118765971 · Cited by 29
Self-citationThe Association of Reproductive Hormones During the Menstrual Period with Primary Dysmenorrhea
Jiang, J., Zhuang, Y., Si, S., Cheng, H., Alifu, X., Mo, M., Zhou, H., Liu, H., & Yu, Y. (2023) · International Journal of Women s Health · doi:10.2147/ijwh.s421950 · Cited by 28
Miller, C. E., Kim, J. H., Kroll, R., Simon, J. A., Soliman, A. M., Thomas, J. W., Xu, Y., Ng, J., & Snabes, M. C. (2024) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2024.06.040 · Cited by 32
Self-citationDatkhayeva, Z., Iskakova, A., Mireeva, A., Seitaliyeva, A., Skakova, R., Kulniyazova, G., Shayakhmetova, A., Koshkimbayeva, G., Sarmuldayeva, C., Nurseitova, L., et al. (2025) · Medicina · doi:10.3390/medicina61050811 · Cited by 29
Endometriosis and ovulatory menstruation: beyond the Sampson principle
Bulun, S. E. (2025) · Journal of Clinical Investigation · doi:10.1172/jci188787 · Cited by 29
Donnez, J., Donnez, O., Tourniaire, J., Brethous, M., Bestel, E., Garner, E. I. O., Charpentier, S., Humberstone, A., & Loumaye, E. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10245794 · Cited by 28
Archer, D. F., Ng, J., Chwalisż, K., Chiu, Y., Feinberg, E. C., Miller, C. E., Feldman, R., & Klein, C. E. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgz086 · Cited by 28
Self-citationLiu, B., Jiang, H., Yuan, T., Luo, J., Zhou, W., Jiang, Q.-Q., & Wu, D. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.650054 · Cited by 27
Gonadotropin-Releasing Hormone Antagonists—A New Hope in Endometriosis Treatment?
Rzewuska, A., Żybowska, M., Sajkiewicz, I., Spiechowicz, I., Żak, K., Abramiuk, M., Kułak, K., & Tarkowski, R. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12031008 · Cited by 27
Efficacy of elagolix in the treatment of endometriosis
Perricos, A., & Wenzl, R. J. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1359258 · Cited by 27
Population Pharmacokinetics of Elagolix in Healthy Women and Women with Endometriosis
Winzenborg, I., Nader, A. M., Polepally, A. R., Liu, M., Degner, J. F., Klein, C. E., Mostafa, N. M., Noertersheuser, P. A., & Ng, J. (2018) · Clinical Pharmacokinetics · doi:10.1007/s40262-018-0629-6 · Cited by 27
Self-citationEndometriosis and Adenomyosis: Modern Concepts of Their Clinical Outcomes, Treatment, and Management
Ottolina, J., Villanacci, R., D’Alessandro, S., He, X., Grisafi, G., Ferrari, S. M., & Candiani, M. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13143996 · Cited by 26
Management of women with endometriosis in the 21st century
Sardo, A. D. S., Becker, C. M., Renner, S. P., Suvitie, P. A., Estadella, J., Vannuccini, S., García-Velasco, J. A., Verguts, J., & Mercorio, A. (2025) · Current Opinion in Obstetrics & Gynecology · doi:10.1097/gco.0000000000001027 · Cited by 31
Pelvic pain correlates with peritoneal macrophage abundance not endometriosis
Gibson, D. A., Collins, F., Leo, B. D., Horne, A. W., & Saunders, P. T. K. (2021) · Reproduction and Fertility · doi:10.1530/raf-20-0072 · Cited by 28
HOXA10 Regulates the Synthesis of Cholesterol in Endometrial Stromal Cells
Yu, M., Tang, J., Huang, Y., Guo, C., Du, P., Li, N., & Quan, Q. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.852671 · Cited by 26
Tian, G., Xu, Y., Luo, Y., Zhu, X., & Lü, J. (2023) · The Journal of Chemical Thermodynamics · doi:10.1016/j.jct.2023.107052 · Cited by 26
Modern view on the diagnostics and treatment of adenomyosis
Moldassarina, R. S. (2023) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-023-06982-1 · Cited by 26
Pohl, O., Marchand, L., Fawkes, N., Gotteland, J., & Loumaye, E. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-01875 · Cited by 26
Yu, E. H., & Joo, J. K. (2022) · Daehan saengsik uihak hoeji/Clinical and experimental reproductive medicine · doi:10.5653/cerm.2022.05603 · Cited by 26
Health-related quality of life improvements in patients with endometriosis treated with elagolix
Taylor, H. S., Soliman, A. M., Johns, B., Pokrzywinski, R. M., Snabes, M., & Coyne, K. S. (2020) · Obstetrics & Gynecology · doi:10.1097/aog.0000000000003917 · Cited by 25
Self-citationSaleh, F., & Taylor, H. S. (2023) · F&S Reports · doi:10.1016/j.xfre.2023.01.008 · Cited by 25
Self-citationEffect of Instructional Supportive Guideline for Improving Women's Awareness towards Endometriosis
Mohamed, W. F., & Hassan, H. E. (2019) · American journal of nursing research · doi:10.12691/ajnr-8-1-5 · Cited by 25
Zajec, V., Mikuš, M., Vitale, S. G., D’Alterio, M. N., Gregov, M., Šarić, M. J., Carugno, J. A., Angioni, S. L., & Ćorić, M. (2022) · Gynecological Endocrinology · doi:10.1080/09513590.2022.2109145 · Cited by 25
Chiney, M. S., Ng, J., Gibbs, J. P., & Shebley, M. (2019) · Clinical Pharmacokinetics · doi:10.1007/s40262-019-00833-6 · Cited by 25
Self-citationG-Protein-Coupled Receptor CXCR7 Is Overexpressed in Human and Murine Endometriosis
Pluchino, N., Mamillapalli, R., Moridi, I., Tal, R., & Taylor, H. S. (2018) · Reproductive Sciences · doi:10.1177/1933719118766256 · Cited by 24
Self-citationWyrwich, K. W., O’Brien, C. F., Soliman, A. M., & Chwalisż, K. (2018) · Reproductive Sciences · doi:10.1177/1933719118789509 · Cited by 24
Various types of adenomyosis and endometriosis: in search of optimal management
Guo, S. (2023) · Fertility and Sterility · doi:10.1016/j.fertnstert.2023.03.021 · Cited by 24
Synergy between Th1 and Th2 responses during endometriosis: A review of current understanding
Chang, L.-Y., Shan, J., Hou, X., Li, D., & Wang, X.-Q. (2023) · Journal of Reproductive Immunology · doi:10.1016/j.jri.2023.103975 · Cited by 24
CXCR4 or CXCR7 Antagonists Treat Endometriosis by Reducing Bone-Marrow Cell Trafficking
Pluchino, N., Mamillapalli, R., Shaikh, S., Habata, S., Tal, A., Gaye, M., & Taylor, H. S. (2019) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.14933 · Cited by 24
Self-citationCurrent and Emerging Medical Treatments for Uterine Fibroids
Chwalisż, K., & Taylor, H. S. (2017) · Seminars in Reproductive Medicine · doi:10.1055/s-0037-1606302 · Cited by 23
Self-citationEndometriosis: a complex systemic disease with multiple manifestations
Taylor, H. S. (2019) · Fertility and Sterility · doi:10.1016/j.fertnstert.2019.06.006 · Cited by 23
Self-citationWang, S.-T., Johnson, S. J., Mitchell, D., Soliman, A. M., Vora, J. B., & Agarwal, S. K. (2019) · Journal of Comparative Effectiveness Research · doi:10.2217/cer-2018-0124 · Cited by 22
Bäurle, S., Nagel, J., Peters, O., Bräuer, N., ter Laak, A., Preuße, C., Rottmann, A., Heldmann, D., Bothe, U., Blume, T., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01862 · Cited by 22
Oskotsky, T., Bhoja, A., Bunis, D. G., Le, B. L., Tang, A., Kosti, I., Li, C., Houshdaran, S., Sen, S., Vallvé-Juanico, J., et al. (2024) · iScience · doi:10.1016/j.isci.2024.109388 · Cited by 21
Self-citationSkorupskaite, K., Hardy, M., Bhandari, H. M., Yasmin, E., Saab, W., & Seshadri, S. (2024) · Human Fertility · doi:10.1080/14647273.2023.2288634 · Cited by 24
Deep pelvic endometriosis: clinical features, diagnosis, and treatment - a comprehensive review
Abıke, F., Tanoğlu, F. B., & Sidar, G. (2025) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-025-08187-0 · Cited by 20
Neri, M., Melis, G. B., Giancane, E., Vallerino, V., Pilloni, M., Piras, B., Loddo, A., Paoletti, A. M., & Mais, V. (2019) · International Journal of Women s Health · doi:10.2147/ijwh.s185023 · Cited by 19
Barretta, M., Vignali, M., Marca, A. L., & Grandi, G. (2024) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2024.2441981 · Cited by 18
Azam, S. S., Vasudevan, S., Bukhari, W. S., Thadhani, J., Tasneem, H., Singh, S., Chijioke, I., de Freitas, B. M., Thammitage, M. B. W., & Motwani, J. (2025) · Cureus · doi:10.7759/cureus.78222 · Cited by 18
Hung, S. W., Gaetani, M., Li, Y., Tan, Z., Xu, Z., Zhang, R., Ding, Y., Man, G. C. W., Zhang, T., Song, Y., et al. (2023) · Journal of Pharmaceutical Analysis · doi:10.1016/j.jpha.2023.09.005 · Cited by 18
Elagolix Pharmacokinetic Profiles in Women With Renal or Hepatic Impairment
Ng, J., Duan, W. R., Marbury, T. C., Schmidt, J. M., & Klein, C. E. (2018) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.640 · Cited by 18
Self-citationEstes, S. J., Soliman, A. M., Yang, H., Wang, J. J. J., & Freimark, J. (2020) · Advances in Therapy · doi:10.1007/s12325-020-01280-7 · Cited by 18
Clinical management of endometriosis
Russo, M. L., Chalif, J., & Falcone, T. (2020) · Minerva Obstetrics and Gynecology · doi:10.23736/s0026-4784.20.04544-x · Cited by 18
Ghosh, D., Filaretova, L. P., Bharti, J., Roy, K. K., Sharma, J. B., & Sengupta, J. (2020) · Reproductive Medicine · doi:10.3390/reprodmed1010004 · Cited by 18
Role of medical treatment of endometriosis
Martone, S., Troìa, L., Marcolongo, P., & Luisi, S. V. (2021) · Minerva Obstetrics and Gynecology · doi:10.23736/s2724-606x.21.04784-5 · Cited by 18
Viviano, M., Benagiano, G., Guo, S., & Pluchino, N. (2024) · Reproductive BioMedicine Online · doi:10.1016/j.rbmo.2024.104321 · Cited by 18
Comprehensive Review of Endometriosis Care
Carey, E. T., Wong, J. M. K., & Khan, Z. (2025) · Obstetrics and Gynecology · doi:10.1097/aog.0000000000006004 · Cited by 17
Endometriosis and Pelvic Pain for the Gastroenterologist
Singh, S. S., Missmer, S. A., & Tu, F. F. (2022) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2021.10.012 · Cited by 17
Tezuka, M., Tamai, Y., Kuramochi, Y., Kobayashi, K., Fushimi, N., & Kiguchi, S. (2022) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/1440-1681.13688 · Cited by 17
Miao, J., Lu, J., Tang, J., & Lu, P. (2022) · Gynecological Endocrinology · doi:10.1080/09513590.2022.2098948 · Cited by 17
A review of phase II and III drugs for the treatment and management of endometriosis
Perrone, U., Evangelisti, G., Laganà, A. S., Bogliolo, S., Ceccaroni, M., Izzotti, A., Gustavino, C., Ferrero, S., & Barra, F. (2023) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2023.2296080 · Cited by 17
Women with endometriosis in the United States: National Survey of Family Growth, 2011–2019
Al-Lami, R. A., Taha, S. A., Jalloul, R. J., & Taylor, H. S. (2024) · Journal of Endometriosis and Uterine Disorders · doi:10.1016/j.jeud.2024.100081 · Cited by 20
Self-citationElagolix in the treatment of endometriosis: impact beyond pain symptoms
Archer, D. F., Soliman, A. M., Agarwal, S. K., & Taylor, H. S. (2020) · Therapeutic Advances in Reproductive Health · doi:10.1177/2633494120964517 · Cited by 17
Self-citationCsirzó, Á., Kovács, D. P., Szabó, A., Szabó, B., Jankó, Á., Hegyi, P., Nyirády, P., Ács, N., & Valent, S. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13226932 · Cited by 16
Mercorio, A., Giampaolino, P., Romano, A., Dällenbach, P., & Pluchino, N. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.950866 · Cited by 16
“Even if the majority of patients were satisfied with this therapy, as many as 40% of patients indicated unsatisfactory improvement of pain symptoms (69).”
BackgroundUpdate on the management of endometriosis-associated pain in France
Fernandez, H., Agostini, A., Baffet, H., Chabbert‐Buffet, N., Descamps, P., Estrade, J.-P., Giraudet, G., Hocké, C., Salle, B., Trémollières, F., et al. (2023) · Journal of Gynecology Obstetrics and Human Reproduction · doi:10.1016/j.jogoh.2023.102664 · Cited by 18
Mikuš, M., Goldštajn, M. Š., Laganà, A. S., Vukorepa, F., & Ćorić, M. (2023) · Pharmaceuticals · doi:10.3390/ph16091315 · Cited by 16
Pokrzywinski, R. M., Soliman, A. M., Chen, J., Snabes, M. C., Diamond, M. P., Surrey, E. S., & Coyne, K. S. (2019) · Fertility and Sterility · doi:10.1016/j.fertnstert.2019.04.031 · Cited by 16
Self-citationEndometriosis and Reproduction: What We Have Learned.
García-Fernández, J., & García-Velasco, J. A. (2020) · PubMed Central · Cited by 16
Medical management of endometriosis
Newmark, A., Luciano, D. E., Ulrich, A., & Luciano, A. A. (2021) · Minerva Obstetrics and Gynecology · doi:10.23736/s2724-606x.21.04776-x · Cited by 16
Stepwise Approach to the Management of Endometriosis-Related Dysmenorrhea
Bohn, J. A., Bullard, K. A., Rodriguez, M. I., & Ecker, A. M. (2021) · Obstetrics and Gynecology · doi:10.1097/aog.0000000000004536 · Cited by 17
Surrey, E. S., Soliman, A. M., Johns, B., Vora, J. B., Taylor, H. S., & Agarwal, S. K. (2020) · ClinicoEconomics and Outcomes Research · doi:10.2147/ceor.s264905 · Cited by 15
Self-citationAbrão, M. S., Surrey, E. S., Gordon, K., Snabes, M. C., Wang, H., Ijacu, H., & Taylor, H. S. (2021) · BMC Women s Health · doi:10.1186/s12905-021-01385-3 · Cited by 15
Self-citationTaylor, H. S., Li, H. J., Carson, S. A., Flores, V. A., Pal, L., Robbins, J., Santoro, N. F., Segars, J. H., Seifer, D. B., Huang, H., et al. (2022) · BMJ Open · doi:10.1136/bmjopen-2021-052043 · Cited by 15
Self-citationOligo-anovulation is not a rarer feature in women with documented endometriosis
Santulli, P., Tran, C., Gayet, V., Bourdon, M., Maignien, C., Marcellin, L., Pocate-Cheriet, K., Chapron, C., & de Ziegler, D. (2018) · Fertility and Sterility · doi:10.1016/j.fertnstert.2018.06.012 · Cited by 15
Fertility Preservation for Adolescents Receiving Cancer Therapies
Appiah, L. A. (2020) · Clinical Obstetrics & Gynecology · doi:10.1097/grf.0000000000000547 · Cited by 15
Pokrzywinski, R. M., Soliman, A. M., Surrey, E. S., Snabes, M. C., & Coyne, K. S. (2020) · Journal of Patient-Reported Outcomes · doi:10.1186/s41687-020-00257-y · Cited by 15
Self-citationNogueira, T. C. M., & Souza, M. V. N. D. (2021) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2021.116340 · Cited by 15
Pokrzywinski, R. M., Soliman, A. M., Chen, J., Snabes, M. C., Taylor, H. S., & Coyne, K. S. (2019) · Journal of Women s Health · doi:10.1089/jwh.2019.7788 · Cited by 15
Self-citationElagolix to medically treat a uterine adenomyoma: A case report
Kavoussi, S. K., Esqueda, A. S., & Jukes, L. M. (2020) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2020.02.027 · Cited by 15
Classification algorithm of patients with endometriosis: Proposal for tailored management
Cosma, S. D., & Benedetto, C. (2020) · Advances in Clinical and Experimental Medicine · doi:10.17219/acem/118849 · Cited by 15
Suleiman, A. A., Nader, A. M., Winzenborg, I., Beck, D., Polepally, A. R., Ng, J., Noertersheuser, P. A., & Mostafa, N. M. (2020) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12560 · Cited by 15
Self-citationDeciding on the appropriate pharmacotherapy for the treatment of endometriosis
Carneiro, M. M. (2022) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2022.2113383 · Cited by 15
Pharmacologic Interventions for Endometriosis-Related Pain
Kou, L., Huang, C., Xiao, D., Liao, S., Li, Y., & Wang, Q. (2025) · Obstetrics and Gynecology · doi:10.1097/aog.0000000000005923 · Cited by 14
The long road of drug development for endometriosis – Pains, gains, and hopes
Liao, Z., Monsivais, D., & Matzuk, M. M. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.10.036 · Cited by 16
Managing the neuroinflammatory pain of endometriosis in light of chronic pelvic pain
Pergolizzi, J. V., LeQuang, J. A., Coluzzi, F., El-Tallawy, S. N., Magnusson, P., Ahmed, R. S., Varrassi, G., & Porpora, M. G. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2425727 · Cited by 15
Mood lability and depression limit oral contraceptive therapy in endometriosis
Cevik, E. C., & Taylor, H. S. (2024) · Fertility and Sterility · doi:10.1016/j.fertnstert.2024.12.011 · Cited by 14
Self-citationCurrent and emerging therapies for endometriosis-associated pain: a review
Tijani, E. O., Ajayi, L. O., Tijani, O. S., Akano, O. P., & Ajayi, A. F. (2025) · Middle East Fertility Society Journal · doi:10.1186/s43043-025-00221-0 · Cited by 14
Metadata
- Authors
- Taylor, H. S., Giudice, L. C., Lessey, B. A., Abrao, M. S., Kotarski, J., Archer, D. F., Diamond, M. P., Surrey, E., Johnson, N. P., Watts, N. B., Gallagher, J. C., Simon, J. A., Carr, B. R., Dmowski, W. P., Leyland, N., Rowan, J. P., Duan, W. R., Ng, J., Schwefel, B., Thomas, J. W., Jain, R. I., & Chwalisz, K.
- Affiliations
- Creighton University (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2017-07-06
- Volume
- 377
- Issue
- 1
- Pages
- 28-40
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2616333165
- Cited by
- 511
- References
- 36
- Citations by year
- 2026: 53 · 2025: 56 · 2024: 62 · 2023: 53 · 2022: 42 · 2021: 67 · 2020: 74 · 2019: 45 · 2018: 40 · 2017: 18
- FWCI
- 56.56
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (publishedVersion, other-oa)
- PubMed (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Creighton Digital Repository (CDR) (submittedVersion)
- Topics
- Health Sciences › Medicine › Reproductive Medicine › Endometriosis Research and Treatment
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Menstrual Health and Disorders
- Health Sciences › Medicine › Obstetrics and Gynecology › Ectopic Pregnancy Diagnosis and Management
- Keywords
- endometriosis, elagolix, GnRH antagonist, dysmenorrhea, estrogen suppression, rescue analgesic consumption, pain management, dose comparison, chronic pelvic pain
- MeSH terms
- Adolescent, Adult, Dose-Response Relationship, Drug, Double-Blind Method, Dysmenorrhea, Endometriosis, Estrogen Antagonists, Female, Humans, Hydrocarbons, Fluorinated, Gonadotropin-Releasing Hormone, Lipids, Middle Aged, Pyrimidines, Bone Density, Premenopause, Pelvic Pain, Hot Flashes, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
